Intarcia enrolls PhIII glucose control study for Type 2 diabetes

Intarcia Therapeutics enrolled its first patients in Phase III trials for its Type 2 diabetes treatment to be delivered underneath the skin. Quintiles partnered with Intarcia to conduct the FREEDOM study of the treatment ITCA 650, which involves the delivery of exenatide via a matchstick-sized osmotic pump placed under the skin, a regimen that is designed to control glucose levels so that self-injections need not be as frequent for diabetics. The treatment would only need to be administered once or twice a year, a fact the company calls "game-changing." More

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…